1. AB0160 Effects of TOFACITINIB (CP-690, 550) on lipid biomarkers in rat adjuvant-induced arthritis (AIA) model and in patients with active rheumatoid arthritis. (23rd January 2014) Authors: McInnes, I.; Kaplan, I.; Boy, M.; Riese, R.; Zuckerman, A.; Clark, J.; Kishore, N.; Brosnan, M.; Zwillich, S.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 646 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0137 Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. (23rd January 2014) Authors: McInnes, I. B.; Kaplan, I.; Boy, M.; Riese, R.; Zuckerman, A.; Gruben, D.; Brosnan, M. J.; Zwillich, S.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial. (23rd January 2014) Authors: Genovese, M.; van Vollenhoven, R.; Wilkinson, B.; Wang, L.; Zwillich, S.; Gruben, D.; Benda, B.; Jones, T.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis. (10th June 2014) Authors: Alten, R.; Strand, V.; Fleischmann, R.; Koncz, T.; Zwillich, S.; Bradley, J.; Gruben, D.; Wilkinson, B.; Krishnaswami, S.; Wallenstein, G. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0148 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies in Japanese Patients across the Rheumatoid Arthritis Clinical Programme. (10th June 2014) Authors: Tanaka, Y.; Takeuchi, T.; Yamanaka, H.; Hirose, T.; Toyoizumi, S.; Zwillich, S.; Geier, J.; Riese, R. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗